Press Releases

12.02.2018

Pfizer Presents Positive 26-Week Data For PF-05280586, A Potential Biosimilar To Rituximab, At The American Society Of Hematology Annual Meeting

11.30.2018

Pfizer Reaches a Global Agreement with AbbVie

11.27.2018

Pfizer Receives Six Months Pediatric Exclusivity for LYRICA® (pregabalin)

11.21.2018

U.S. FDA Approves DAURISMO™ (glasdegib) for Adult Patients with Newly-Diagnosed Acute Myeloid Leukemia (AML) for Whom Intensive Chemotherapy is Not an Option

11.19.2018

Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer

11.02.2018

U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC

10.30.2018

PFIZER REPORTS THIRD-QUARTER 2018 RESULTS

10.28.2018

Pfizer Announces Clinical Development Agreement with Novartis to Advance the Treatment of NASH

10.25.2018

CANCER THERAPEUTICS CRC SIGNS AGREEMENT TO ENABLE PFIZER TO DEVELOP NOVEL CANCER DRUGS

10.23.2018

Complete Results from First Study in Ongoing Phase 3 Program for Tanezumab Demonstrated Significant Improvement in Pain and Function in Osteoarthritis Patients

10.23.2018

Bain Capital and Pfizer Create Cerevel Therapeutics, New CNS Company

10.20.2018

Pfizer Presents Overall Survival Data From PALOMA-3 Trial of IBRANCE® (palbociclib) in Patients With HR+, HER2- Metastatic Breast Cancer